New York City, NY – According to filings with the U.S. Securities and Exchange Commission, Intelligencia is raising $13,782,708.00 in new funding. Sources indicate as part of senior management President, Evangelos Vergetis played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Intelligencia
Intelligencia.ai uses Artificial Intelligence to de-risk drug development. Our platform focuses on estimating the risk of clinical trials, and interpreting the multitude of factors that contribute to that risk. We therefore aim to bridge the gap between innovation and risk reduction, with the ultimate goal of bringing novel therapies to patients faster. Our interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers brings together and interprets disparate data across the life sciences industry. Our platform offers a suite of functionalities that provide unprecedented data clarity and Machine-Learning fueled predictions to enable critical decision making. Diseases will impact nearly every individual. At Intelligencia, we work to make a difference.

To learn more about Intelligencia, visit http://www.intelligencia.ai/

Contact:
Evangelos Vergetis, President
212-653-8329
https://www.linkedin.com/in/vangelisvergetis/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved